Analysis

Mid-day market update: Dow falls 40 points, Aprea Therapeutics shares surge

Midway through trading Wednesday, the Dow traded down 0.12% to 34,259.48 while the NASDAQ rose 0.20% to 14,100.31. The S&P also fell, dropping 0.05% to 4,244.41.

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 33,486,910 cases with around 600,280 deaths. India confirmed a total of at least 29,633,100 cases and 379,570 deaths, while Brazil reported over 17,533,220 COVID-19 cases with 490,690 deaths. In total, there were at least 176,682,210 cases of COVID-19 worldwide with more than 3,823,780 deaths, according to data compiled by Johns Hopkins University.

Leading and Lagging Sectors

Health care shares climbed 0.4% on Wednesday. Meanwhile, top gainers in the sector included Kindred Biosciences, Inc. KIN 45.15%, up 45%, and Opthea Limited OPT 20.96%, up 45%.

In trading on Wednesday, financial shares fell 0.7%.

Top Headline

Elanco Animal Health Incorporated ELAN 3.71% agreed to acquire Kindred Biosciences Inc KIN 45.15% for $9.25 per share, or approximately $440 million.

The price represents a premium of 52% based on the 30-day average.

Equities Trading UP

Kindred Biosciences, Inc. KIN 45.15% shares shot up 45% to $9.19 after Elanco announced an agreement to acquire the company for $9.25 per share.

Shares of Aprea Therapeutics, Inc. APRE 20.02% got a boost, shooting 39% to $6.76 after the company announced that the Phase 1/2 trial evaluating eprenetapopt in acute myeloid leukemia (AML) has met the pre-specified primary efficacy endpoint of complete remission (CR) rate.

BriaCell Therapeutics Corp. BCTX 11.44% shares were also up, gaining 16% to $7.01 after the company announced it is expanding its breast cancer platform into prostate, melanoma and lung cancers.

Equities Trading DOWN

Paratek Pharmaceuticals, Inc. PRTK 12.46% shares tumbled 14% to $8.80. Paratek Pharmaceuticals initiated Phase 2b trial evaluating Nuzyra (omadacycline) for Nontuberculous Mycobacterial (NTM) Pulmonary Disease caused by Mycobacterium abscessus complex (MABc).

Shares of Inhibikase Therapeutics, Inc. IKT 26.64% were down 24% to $3.08 after the company priced an underwritten public offering of 15 million shares at $3/share for gross proceeds of approximately $45 million.

Blue Apron Holdings, Inc. APRN 20.89% was down, falling 19% to $4.4750 after the company priced public offering of 4.706 million shares of Class A common stock at $4.25 per share.

Commodities

In commodity news, oil traded up 0.4% to $72.44, while gold traded up 0.2% to $1,860.

Silver traded up 0.8% Wednesday to $27.91 while copper rose 1.4% to $4.3915.

Euro zone

European shares were mixed today. The eurozone’s STOXX 600 gained 0.19%, the Spanish Ibex Index fell 0.28% and the German DAX 30 fell 0.13%. Meanwhile, the London’s FTSE 100 gained 0.14%, French CAC 40 climbed 0.05% and Italy’s FTSE MIB rose 0.05%.

UK’s producer prices rose 4.6% year-on-year in May, while consumer price inflation rate increased to 2.1% year-over-year.

Economics

Housing starts rose 3.6% to an annualized rate of 1.572 million in May, while building permits fell 3.0% to a 1.681 million rate.

US import prices increased 1.1% in May, while prices for exports climbed 2.2%.

US crude-oil inventories dropped 7.4 million barrels last week, the Energy Information Administration said.

The Federal Reserve will announce its policy decision at 2:00 p.m. ET.

The Fed Chairman Jerome Powell will hold a press conference at 2:30 p.m. ET.

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.


RELATED CONTENT

Loading ...



Copyright © 2024 FOREXSTREET S.L., All rights reserved.